{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpodcasts.prevmedhealth.com%2Fepisodes%2Fshingrix-pt-3-shingrix-3mIb2XQY","width":444,"version":"1.0","type":"rich","title":"Shingrix pt 3, Shingrix","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/3512c98c-c29a-485f-8f25-7fec2feffd3f/3f5d6675-fa70-408e-9506-1f60e9b38cd0/shingrix-pt-3.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/faf0aaf3-563f-4e56-bd0d-1ecef5a08b1c\" height=\"200\" width=\"100%\" title=\"Shingrix pt 3, Shingrix\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This is part 3 of a series on Shingrix, the new vaccine for Singles. In a new practice for the FDA and CDC's ACIP, they actually recommended this new vaccine over the existing competitor, Zostavax. This was despite an absence of post-market safety experience. Why? This is a huge improvement in long-term efficacy of preventing this important and devastating public health problem which causes disability, pain, and death. "}